SCHEMBL21964048

SCHEMBL21964048

CCOC(=O)CN(C(=O)C1(C(F)(F)F)CCC1)C1CCCN(C(=O)O)C1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.39
CHRM1 P11229 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
ALDH1A1 P00352 3/20 0.32
POLB P06746 2/20 0.31
NPC1 O15118 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
HTT P42858 1/20 0.30
TACR3 P29371 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28602133 0.88 ALDH1A1 (0.39) L3MBTL1CHRM1MEN1KMT2ASMN1; SMN2
SCHEMBL28602131 0.88 ALDH1A1 (0.39) L3MBTL1CHRM1MEN1KMT2ASMN1; SMN2
SCHEMBL22010875 0.87 SMN1; SMN2 (0.33) L3MBTL1CHRM1MEN1KMT2ASMN1; SMN2
SCHEMBL21964180 0.84 L3MBTL1 (0.42) L3MBTL1CHRM1MEN1KMT2ASMN1; SMN2
SCHEMBL21964122 0.80 L3MBTL1 (0.37) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL21964077 0.80 L3MBTL1 (0.42) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL21964127 0.79 L3MBTL1 (0.39) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL24220798 0.78 MEN1 (0.40) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL28594990 0.78 MEN1 (0.40) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL28604437 0.77 ALDH1A1 (0.37) L3MBTL1CHRM1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220023281-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS THE UNIVERSITY OF SHEFFIELD (GB) 2022-01-27 US disclosed
EP-3880679-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS The University Of Sheffield (GB) 2021-09-22 EP disclosed
WO-2020099882-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS THE UNIVERSITY OF SHEFFIELD (GB) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220023281-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS MC2R, AGTR2, AGTR1 L3MBTL1 4019/4885CHRM1 47/4885MEN1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.